Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: E_K_S who wrote (40337)	8/31/2011 4:17:48 PM
From: E_K_S	Read Replies (3) of 78705

Eli Lilly & Co. (LLY) Closed out my LLY position originally acquired 8/2009 & 4/2010. May reenter at lower prices (below $35). My drug stock positions include PFE, MRK, GSK, BMY & ABT. Out of COV earlier this year too. LLY was looking at PFE's Pet drug subsidiary as this was a business the company was pursuing for growth. Nothing has come out of their discussions. Long term I see it as a net positive for LLY but with the stock's recent 10% move higher and no announcement regarding their Pet Drug expansion, I decided to book my profits and wait on the sidelines. I would like to redeploy these funds back into the drug/health care sector to maintain my exposure to the industry. I am watching JnJ and AZN but neither I consider value buys at current prices. Any other suggestions welcomed. EKS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next